IMRX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
19.0M
+23.9%
15.3M
+11.5%
13.8M
-10.6%
15.4M
+4.2%
14.8M
R&D
14.0M
+31.5%
10.6M
+15.0%
9.3M
-14.8%
10.9M
+4.0%
10.5M
SG&A
5.0M
+6.7%
4.7M
+4.3%
4.5M
-0.3%
4.5M
+4.9%
4.3M
Operating Income
-19000408
-23.9%
-15335034
-11.5%
-13752719
+10.6%
-15380706
-4.2%
-14757894
EBITDA
-18908638
-24.0%
-15246315
-11.5%
-13669513
+10.6%
-15294549
-4.3%
-14666051
Net Income
-17270427
-28.3%
-13460895
-16.2%
-11580010
+22.6%
-14964875
-3.7%
-14433881
EPS (Basic)
$-0.27
-28.6%
$-0.21
-16.7%
$-0.18
+52.6%
$-0.38
+5.0%
$-0.40
EPS (Diluted)
$-0.27
-28.6%
$-0.21
-16.7%
$-0.18
+52.6%
$-0.38
+5.0%
$-0.40
Shares (Diluted)
64.7M
+0.1%
64.7M
-0.3%
64.9M
+63.5%
39.7M
+10.2%
36.0M
Immuneering (IMRX) โ€” Financials